Page 101 - The Flying Publisher Guide to Hepatitis C Treatment

Appendix – Selected drug profiles | 101

7. Appendix – Selected drug profiles

Simona Ruta and Costin Cernescu

The following highlights do not include all the information
needed to use the drugs safely and effectively. See full
prescribing information for each drug.

Pegasys™
(pegylated interferon alfa-2a 40 kD)
Drug class: Cytokine, interferon.
Manufacturer: Hoffmann-La Roche, Inc.
Indications: Chronic hepatitis C, possibly also for hepatitis B.
Pegasys, alone or in combination with ribavirin (Copegus), is
indicated for the treatment of adults with CHC who have
compensated liver disease and have not been previously treated
with IFN alfa. Efficacy has also been demonstrated in subjects
with histological evidence of cirrhosis (Child Pugh class A) and in
subjects with clinically stable HIV disease and CD4 count
>100 cells/mm2.
Pegasys is also indicated for the treatment of adult patients with
HbeAg-positive and HbeAg-negative chronic hepatitis B who
have compensated liver disease and evidence of viral replication
and liver inflammation.
Dose: 180 µg, once per week.